Teva to pay $225M to settle cholesterol drug price-fixing charges
The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug. The U.S. Department of Justice said the agreement also requires Teva to divest its business making and selling the drug, pravastatin, a generic version of the brand-name medicine Pravachol.
Another generic drug maker, Glenmark Pharmaceuticals, agreed to pay a $30 million criminal penalty and to divest its pravastatin business as well.
![](https://kbin.life/media/cache/resolve/entry_thumb/2e/56/2e56657ee24f21d57b903b74980d0ea3e98ed6e7634a458d51a7b797fa6010ea.jpg)